Study drug for relapsed or treatment-resistant T-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This early-phase (Phase 1) study tests ONO-4685 in adults whose T-cell lymphoma has come back or did not respond to treatment. It aims to find a safe dose and see whether it can shrink lymphoma in people with limited options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You (or your legal decision-maker) can sign consent before any study checks
- Your lymphoma type is a T-cell lymphoma (certain kinds of peripheral or skin T-cell lymphomas)
- You have tried at least two prior cancer medicines that work through the body
- If you have peripheral T-cell lymphoma, you have at least one measurable tumor site; if you have skin T-cell lymphoma, your disease can be assessed by the study’s skin-lungoma measures
- You can do basic daily activities fairly well (ECOG score 0–2) and have at least 3 months expected survival
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests OBI-3424, an investigational medicine, in adults and children with relapsed or hard-to-treat T-cell acute leukemia or certain T-cell lymphoma. It may help by shrinking cancer when standard treatments have not worked.
This trial tests a new drug, ONO-4685, for people with certain types of T cell lymphoma or chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) that has not responded to standard treatments or cannot tolerate them. The goal is to see if the drug is safe and tolerable.
This Phase 1 trial tests the safety and early signs of benefit of OC-1 in people with relapsed or hard-to-treat T-cell leukemia/lymphoma (T-ALL/LL) that has a CD1a marker. You may be considered if standard treatments didn’t work or the cancer returned, and if your organs and infections are controlled.
This study tests a new cancer treatment called CT1190B for people with certain types of B-cell lymphoma that have not responded to or came back after other treatments. The goal is to see if it can help shrink or control the lymphoma.
This Phase 1/2 study tests AVM0703 in people ages 12+ with certain lymphoid cancers that have returned or not responded to treatment. It may help shrink the cancer or control it when other treatments have failed or are not possible.
This trial is testing several new drug combinations for people with peripheral T-cell lymphoma that has come back or not responded to treatment. It aims to find new options that may work better.
Hear when a new Relapsed or Refractory T Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.